Shandong Peixue Bioengineering Co., Ltd. announced that it will receive CNY 60 million in an equity round of funding through capital increase on October 23, 2022. The company has signed agreement with Shandong Sanyuan Biotechnology Co.,Ltd. The CNY 5 million will go to the registered capital and the rest CNY 55 million will go to capital reverse. The registered capital change from CNY 20 million to CNY 25 million.

The transaction is scope of approval by the general manager of the company, and does not need to be submitted to the board of directors and the general meeting of shareholders for deliberation.